Company Overview and News
YY Inc. (NASDAQ:YY) continues to fall, even as the Chinese, video-based social media company increases its profits. The YY stock price has now dropped by more than 55% since achieving its 52-week high in January.
WB BABA HUYA MOMO BIDU YY SNAP
Chinese search engine Baidu Inc has become the first Chinese company to join an artificial intelligence (AI) ethics group led by top U.S. tech firms, amid wider political clashes over AI competition between China and the United States.
FB GOOGL AAPL MSFT GOOG BIDU
Fund managers in October turned the most pessimistic on global growth prospects since the depths of the financial crisis in the fall of 2008, but aren’t yet negative enough to offer a contrarian buy signal, according to Bank of America Merrill Lynch.
FB BABA GOOGL 0700 AAPL NFLX GOOG BIDU
The investment in NetEase Cloud Music comes amid Baidu’s stepped-up efforts to build an ecosystem of content and battle for user attention as consumers upgrade their spending habits
In the last five years, Netflix (NASDAQ:NFLX) has gone from being compared with CBS (NYSE:CBS) to being compared with Walt Disney (NYSE:DIS), and now Netflix’s spending trends are more similar to those of Disney than CBS. Can Netflix stock meaningfully advance despite the company’s significantly higher spending trends? Yes, it can, because the company’s overseas business will enable the momentum of Netflix stock to continue.
CBS FOX FB CMCSA TWX NFLX TWC WMT AMZN T GOOGL AAPL TSLA BIDU DIS
U.S. equities were under pressure again on Thursday as higher interest rates continued to rout sentiment and fuel worries that the Federal Reserve is about to snuff out the bull market and economic expansion. Things were harrowing Wednesday night, with the Dow Jones Industrial Average down some 1,000 in the after-hours session. President Trump was quick to blame the selloff on the Federal Reserve, who he claims is tightening policy too quickly.
FB AMZN GOOGL NFLX GOOG BIDU
2018-10-13 investorplace - 1
The past few months have been miserable for Alibaba Group Holding (NYSE:BABA) shareholders. There’s no getting around it. BABA stock is down 31% from its June high, and given its momentum and the backdrop of bad news, things could get worse before they get better.
JD BABA DB BIDU
Let’s call a spade a spade: it’s been the unexpected revival of a left-for-dead Advanced Micro Devices (NASDAQ:AMD) that’s made life miserable for Intel (NASDAQ:INTC) shareholders of late. Although Intel stock was up as much as 24% for the year as of June, another batch of new products from AMD has taken the Intel stock price from more than $57 to less than $46.
BC94 SMSN AMD AAPL MS INTC BIDU SMSD
2018-10-11 investorplace - 5
Iqiyi (NASDAQ:IQ), a Chinese video streaming platform service, has seen quite a bit of action since coming public in late March. On the debut, the shares fell nearly 14%. Then buyers came in and boosted IQ stock to a high of $46.23. But alas, it would not hold. IQ would eventually fade to about $25. Still, it is a respectable 39% above the initial offering price.
BABA IQ NFLX BIDU
Chinese chat app Bullet Messenger – touted as an upstart rival to Tencent Holdings Ltd’s hugely popular WeChat – says its app has been removed from Apple Inc’s App Store just months after its launch due to a copyright complaint.Beijing Kuairu Technology, Bullet’s owner, said in a social media posting on Tuesday that it was forced to pull the app after complaints were raised about image content provided by a partner.
0700 AAPL BIDU
Chinese chat app Bullet Messenger - touted as an upstart rival to Tencent Holdings Ltd's hugely popular WeChat - says its app has been removed from Apple Inc's App Store just months after its launch due to a copyright complaint.
0700 AAPL BIDU
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to BIDU / Baidu, Inc. on message board site Silicon Investor.
|Baidu (BIDU)||Baidu (BIDU)||Baidu (BIDU)|
as of ET